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CTL = cytotoxic T lymphocyte; EBV = Epstein-Barr virus; ELISPOT = enzyme-linked immunospot; FACS = fluorescence-activated cell sorting;
HLA = human leukocyte antigen; IFN = interferon; LCMV = lymphocytic chorio meningitis virus; LDA = limiting dilution analysis; MHC = major histo-
compatibility complex; TCR = T-cell receptor.
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Introduction
MHC molecules are highly polymorphic glycoproteins that
are expressed at the cell surface after assembly within the
cell, together with beta 2 microglobulin and short antigenic
peptide fragments. This combination can then be recog-
nized by CD8+ cytotoxic T lymphocytes (CTLs); specificity
for a particular MHC/peptide combination is conferred by
the TCR, which is an immunoglobulin-like molecule. CTLs
play a major role in the adaptive immune response to intra-
cellular infections and tumours, specifically killing appropri-
ate target cells and also releasing pro-inflammatory
cytokines. The principal human leukocyte antigen (HLA)
MHC class I alleles are denoted HLA A, HLA B and HLA
C, although a number of MHC class I-like molecules have
also been described. CTLs can be detected according to
their function, for example in killing assays or by analysis of
cytokine production, according to either their antigenic
specificity (using MHC class I multimers) or their pheno-
type (i.e. their TCR or other expressed molecules).
The traditional method for functional analysis of antigen-
specific CTLs is the cytotoxic T cell lysis assay. This
method is based on the ability of CTLs to lyse target cells
bearing the appropriate MHC and peptide antigen in vitro.
Such assays usually require a period of in vitro culture with
antigen, after which quantitation and phenotypic interpreta-
tion is difficult. The limiting dilution analysis (LDA) is a mod-
ified CTL assay that gives a quantitative measure of the
number of precursor CTLs. Antigen-specific T cells are first
serially diluted and then cultured until the cells have multi-
plied to a sufficient number to perform CTL lysis assays.
The number of precursor CTLs can be estimated from the
lowest dilution at which CTL activity can no longer be
detected. Because the LDA only detects the portion of
cells that are able to proliferate and kill targets after in vitro
culture, it may result in a significant underestimation of the
total number of antigen-specific CTLs.
Several other methods have also been used to estimate
antigen-specific CTLs. The numbers of specific transcripts
for a given T cell receptor (TCR) can be quantified using
molecular techniques. This gives information about T cell
phenotype and clonality, but not about antigen specificity
or function [1,2]. The frequency of CD4+ or CD8+ T cells
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secreting IFN-γ in response to a particular antigen can be
detected by the enzyme-linked immunospot (ELISPOT)
assay [3]. The number of T cells producing a given
cytokine in the presence of specific peptides can also be
measured by flow cytometry [4]. These techniques give
information about both specificity and function, but both
are limited because they detect only the CTLs releasing a
particular cytokine. Furthermore, the results from these
methods have failed to answer some questions, such as
whether individual T cell clones of the same specificity
have identical cell surface phenotypes and cytokine-pro-
ducing profiles. The MHC class I tetrameric complex tech-
nology provides an ideal tool to address these issues and
can be used to follow the course of T cell response to the
challenge of a particular antigen.
Development of MHC tetrameric complex
technology
The MHC class I tetrameric complex technique was intro-
duced by Altman and Davis in Stanford, USA, and their
collaborators in Oxford, UK [5]. The principle of the tech-
nique is that peptide/MHC complexes, as TCR ligands, can
be used to identify T cells with particular antigenic specificity.
In vitro, a single, soluble peptide/MHC complex has a low
affinity for its corresponding TCR, resulting in a weakly
bound complex with a rapid dissociation rate [6]. MHC class
I/peptide multimers, however, can greatly enhance the avidity
of the binding. Such tetrameric complexes can be tagged
with fluorescent dyes, allowing individual T cells to be identi-
fied by flow cytometry analysis. If the specific T cell is co-
tagged with different fluorescent-conjugated antibodies that
are specific for cell surface markers (cytokine or chemokine)
the phenotype of the cell can be elucidated simultaneously.
Perspective (what it can do)
MHC class I tertrameric complex technology has been
used to study immune responses to tumours and viral
infections, and to probe the mechanism underlying
autoimmnune disease. Tetramers have been used to stain
peripheral blood lymphocytes and other cell types [7,8],
cell suspensions made from tissue samples, and tissue
sections [9,10]. Evidence of a role for CTLs in the control
of HIV infection has been provided using tetrameric
complex technology [7,11]. Thus, HLA class I tetramer
staining has shown that the frequency of HIV-1-specific
CTLs in the blood of HIV-infected individuals is inversely
correlated to the RNA viral load in the plasma [11].
By co-staining cells with MHC class I tetrameric complexes
as well as antibodies for cell surface markers (cytokines
and chemokines), a considerable amount of information
about CTL phenotype can be obtained. Using CMV- and
HIV-specific tetramers to stain CD8+ T cells from the same
HIV-infected donor, Appay et al found that CD8+ T cells
that are specific for both HIV and CMV can secrete antiviral
cytokines in response to stimulation by their respective
antigens [12]. However, HIV-specific CD8+ T cells express
a much lower level of perforin than CMV-specific CD8+ T
cells. Perforin is an important molecule for CTL lysis and
promotes the cell death through pore formation in the cell
membrane. This defect in perforin production may con-
tribute to the impaired function of HIV-specific CD8+ T
cells in clearing virus-infected cells [12].
Viral infection can induce massive increases in the number
of T cells. Class I tetrameric complex staining has been
used to determine if this expansion is antigenic specific. In
peripheral blood from a patient with primary Epstein-Barr
virus (EBV) infection, CD8+ CTLs that are specific for a
single EBV epitope may comprise up to 44% of the total
CD8+ T cells [13].
Initially it was thought that much of the increase in T cell
numbers during the response to viruses is not antigen
specific, but represents bystander activation or cross
reactivity to the stimulation of non-specific antigens. In
order to address this issue, Murali-Krishna et al used MHC
class I tetrameric complexes of a lymphocytic chorio
meningitis virus (LCMV) epitope to stain CTLs from
samples collected during primary and secondary murine
LCMV infection. Large increases in numbers of CD8+ T
cells were observed, and the majority of them were LCMV
antigen specific. When mice were first primed with LCMV
then later challenged with heterologous vaccine virus, the
number of LCMV-specific CTLs did not increase [14].
Tetramer technology has therefore shown, at least in this
model, that bystander activation does not occur to a signif-
icant extent. This calls into question its importance as a
general immunological phenomenon.
MHC class I multimers and the response to tumours
Direct evidence for the role of CTLs in the immune response
to tumours has been obtained using MHC class I tetrameric
complex technology. In patients with chronic myelogenous
leukaemia treated with either IFN-α-2b or allogeneic bone
marrow transplantation, tumour-specific CTLs have been
detected using specific MHC class I tetramers complexed
with PR1 (a peptide derived from proteinase 3). The pres-
ence of PR1-specific T cells correlates with disappearance
of the tumour (by cytogenic analysis) after treatment [15].
Theoretically, CTLs with specificity against tumours could be
expanded ex vivo and then reinfused as therapy for tumour
patients. In practice, however, it has proved difficult to isolate
sufficient CTLs due to their low frequency. Single cell FACS
of MHC class I tetrameric complex-stained CTLs has proved
to be an efficient method of obtaining significant numbers of
melanoma-specific CD8+ CTLs, which kill in vitro, and this
precedure could be utilised for therapy [8].
Detection of CTLs in autoimmune disease
Although CTLs play an important role in protecting the
body from pathogens, they can occasionally attack theirc
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
r
e
s
e
a
r
c
h
 
a
r
t
i
c
l
e
own body to cause self-damage, a phenomenon seen in
some MHC-class-I-related autoimmune diseases. Using
MHC class I tetrameric technology, Ogg et al showed that
in the blood of patients with vitiligo (an autoimmune condi-
tion charactarized by loss of epidermal melanocytes) HLA-
A2-restricted melanA-specific CTLs expressed high levels
of cutaneous lymphocyte-associated antigen which is a
skin-homing receptor. This receptor was absent from the
CTLs in an HLA-A2 positive normal control. This study has
lead to the suggestion that lack of homing receptors on
the surface of auto-reactive CTLs could be a mechanism
to maintain peripheral tolerance in vivo [16].
The strongest association of HLA class I with rheumatic
disease is that of HLA B27 with the spondyloarthritides.
To determine the role that class I multimers can play in elu-
cidating the pathogenesis of these conditions, tetramers
of HLA B27, complexed with beta 2 microglobulin and an
influenza epitope (Fig. 1a), have been used to stain both
HLA B27-restricted CTLs (Fig. 1b) and cells transfected
with TCRs from such cells [17]. If disease results from an
HLA-B27-restricted response to an “arthritogenic”
peptide or peptides, it should be possible to detect and
monitor HLA-B27-restricted peptide-specific CTLs in the
blood and joints of these patients. Unfortunately such
arthritogenic peptides have not been conclusively identi-
fied, although a number of candidates have been pro-
posed. These include peptides derived from Yersinia [18]
and self-peptides [19], including one derived from HLA
B27 itself. Responses to these peptides have been
detected by both CTL lysis assay and ELISPOT. It should
now be possible to use HLA B27/peptide tetrameric com-
plexes to stain directly patient blood and synovial material
ex vivo, giving information about the frequency and pheno-
type of such cells in both patients with spondyloarthropa-
thy and healthy controls.
MHC class I-restricted T cell responses in rheumatoid
arthritis
Callan et al have used tetrameric complex technology to
demonstrate the presence of a high frequency of EBV-
specific HLA-class I-restricted CTL in the joints of patients
with rheumatoid arthritis [20]. Whilst not necessarily
implying a direct pathogenic role for such cells, this
finding gives an intriguing insight into the specificity of
T cells in the arthritic joint.
Other applications of tetrameric complex technology
The application of tetrameric complex technology is not
limited to the identification of classical MHC-class-I-
restricted T cell responses. The extension of the use of
this technology has enabled the identification of the
ligands for HLA-E (a non-MHC-class I molecule) as the
natural killer cell receptors CD94/NKG2A, B and C [10].
MHC class I tetrameric complex technology has also been
used to address some fundamental questions in immunology
studies. It was well understood that secondary humoral and
cellular immune responses are stronger than they are after
primary antigenic challenge. Savage et al have provided evi-
dence of a qualitative difference between primary and sec-
ondary effector T cells with respect to affinity. Kinetic
analysis of tetrameric complex binding to TCR showed that,
over the course of an immune response, T cell clones were
selected that had higher affinity and longer duration of
binding to the MHC class I-peptide complex [21].
Tetrameric complex technology has now also been
adapted, despite numerous technical difficulties, to con-
struct MHC class II tetrameric complexes. Tetramers of
HLA DR4 complexed with type II collagen, for example,
have been made and used to detect DR4-restricted
peptide-specific CD4+ helper T cells [22]. These results do
Available online http://arthritis-research.com/content/3/5/265
Figure 1
Model of an HLA/peptide tetrameric complex and its use to stain specific cytotoxic T cells. (a) Molecular model of an HLA/peptide tetrameric
complex. Here HLA B*2705, the molecular subtype of HLA B27, has been refolded with beta 2 microglobulin and the influenza nucleoprotein
peptide NP383-391. Four biotinylated complexes are shown together with one streptavidin molecule (here without a fluorochrome). (b) Example of
HLA-B27/peptide tetrameric complex tetramer staining. Positive FACS staining (shown infilled) for an HLA B27-restricted Influenza NP-specific
CTL line is shown. not, however, suggest that type 2 collagen-specific T cells
are driving the pathogenic process in rheumatoid arthritis.
Short technical description
A fusion protein containing the extracellular domains of a
MHC class I heavy chain together with a 13-amino acid C-
terminal tag (that allows site-specific biotinylation), is
expressed in E.coli. This fusion protein is refolded by dilu-
tion in urea in vitro in the presence of beta 2-microglobulin
and specific peptide. Biotinylation of the C-terminal tag is
then carried out using the BirA enzyme (Fig. 2). Since strep-
tavidin has 4 biotin binding sites, a tetrameric complex is
generated by adding pycoerythrin-conjugated or fluores-
cein-conjugated extravidin streptavidin. Use of phycoerythrin
as a fluorescent marker has given better definition than fluo-
rescein. Figure 1a shows a model of a tetrameric complex.
Tetrameric complexes are relatively stable at 4°C for
periods of weeks to months. After titration to determine
the optimum concentration required, tetramers are used
directly to stain viable cells, and the results analysed by
flow cytometry. There is little or no non-specific binding at
temperatures of 4–37°C.
Address of full information and technical help
A detailed technical description is given by Casares et al
[23] and Ogg [24].
An example
An example of FACS staining of a human HLA B27-
restricted CTL line with an HLA B27 tetramer is shown in
figure 1b.
Limitations
Individual MHC/peptide tetrameric complexes have to be
produced separately, and production is both technically
difficult and time consuming. These complexes have a
limited storage stability. Flow cytometry equipment is
required for analysis of tetrameric staining.
Future developments
MHC class I tetrameric complex technology is becoming
an indispensable tool for studying T cell responses to both
foreign and self antigens. New applications in the elucida-
tion of mechanisms of tumour evasion and autoimmunity
are rapidly being developed, which will be directly applica-
ble to arthritis research. Examples might include the devel-
opment of tetrameric-complex-based libraries to attempt
to identify arthritogenic peptide antigens in spondyloarthri-
tis. Tetrameric complexes tagged with toxins could be
used to specifically target infected, autoimmune or malig-
nant cells [23].
Conclusion
MHC class I tetrameric complex technology is proving to
be a valuable tool that can be used to study antigen-spe-
cific T cell response in viral infection, tumour evasion and
autoimmune disease. In the near future, MHC class I
mutimers may have a role in immunotherapy; fighting
against infections, autoimmune disease and cancer.
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